Articles

Hybrid closed-loop (HCL) system combines technology of CGM and insulin pumps, and a personalized, model-predictive control algorithm to deliver insulin day and night.

One-year, randomized study shows lower HbA1c, blood glucose, blood pressure and body weight without significant increase in hypoglycemia.

By Sheri R. Colberg, PhD, FACSM
A topic that comes up frequently nowadays is the use of diabetes technologies with exercise. When I surveyed close to 300 active individuals with diabetes, more than 60 percent used an insulin pump (which is well above the national average), but even more of these exercisers—over 75 percent—wear a continuous glucose monitoring (CGM) device (1). The technology fervor has grown even louder since the FDA recently granted approval in the United States to an implantable, three-month CGM sensor called Eversense (made by Senseonics). Can active people benefit from using these CGM and other devices, especially when active?

New mobile app from Medtronic, Sugar.IQ™, applies AI technology from IBM Watson Health to help people with diabetes make more informed decisions.

DEPICT-2 study of more than 800 people worldwide indicates positive results without added risk of severe hypoglycemia, but slight increase in DKA events.

The FDA approved the 90-day version of the implantable CGM Sensor.

For those who use insulin, accuracy is one of the most important things to consider when using a CGM.

“Simple,” “Accurate,” and “Effective” were the words ADA presenters used to describe Dexcom G6, a new continuous glucose monitor (CGM) system.

A dual-hormone, artificial pancreas delivering rapid insulin and the drug pramlintide improved glucose management and reduced glucose variability in adults with type 1 compared to an insulin-only, first-generation artificial pancreas.

Investigation into the effect of surgery, from mortality to length of hospital stay, on patients who have diabetes with consistently high blood glucose.